Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 15/20 | 0.35 |
| ▸ | IL1RN | P18510 | 1/20 | 0.35 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.35 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.35 |
| ▸ | VEGFA | P15692 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15262548 | 1.00 | EPAS1 (0.35) | EPAS1IL1RNERAP2ERAP1VEGFA | |
| SCHEMBL29944761 | 1.00 | EPAS1 (0.35) | EPAS1IL1RNERAP2ERAP1VEGFA | |
| SCHEMBL20185074 | 0.78 | IL1RN (0.50) | EPAS1IL1RNERAP2ERAP1 | |
| SCHEMBL23142120 | 0.78 | MAP3K14 (0.39) | EPAS1IL1RNERAP2ERAP1CYP1A2 | |
| SCHEMBL15276006 | 0.78 | MAP3K14 (0.39) | EPAS1VEGFA | |
| SCHEMBL23142099 | 0.78 | MAP3K14 (0.39) | EPAS1IL1RNERAP2ERAP1CYP1A2 | |
| SCHEMBL23142126 | 0.78 | MAP3K14 (0.39) | EPAS1IL1RNERAP2ERAP1CYP1A2 | |
| SCHEMBL31359414 | 0.78 | IL1RN (0.35) | EPAS1IL1RNERAP2ERAP1CYP1A2 | |
| SCHEMBL30239732 | 0.78 | IL1RN (0.50) | EPAS1IL1RNERAP2ERAP1 | |
| SCHEMBL16556089 | 0.77 | EPAS1 (0.35) | EPAS1IL1RNERAP2ERAP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025077773-A1 | NOVEL TYPE I TOPOISOMERASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊维康医药有限责任公司 | 2025-04-17 | — | — | WO | disclosed |
| CN-118290330-A | Amide derivative and application thereof in medicine | 成都百裕制药股份有限公司 | 2024-07-05 | — | — | CN | disclosed |
| US-11976054-B2 | Amide derivative and preparation method therefore and use thereof in medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2024-05-07 | — | — | US | disclosed |
| CN-117105890-A | Amide derivative, preparation method thereof and application thereof in medicine | 成都百裕制药股份有限公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-3601216-B1 | SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-25 | — | — | EP | disclosed |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | CHENGDU BAIYU PHARMACEUTICAL CO., LTD. (CN) | 2022-12-29 | — | — | US | disclosed |
| EP-4059930-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Chengdu Baiyu Pharmaceutical Co., Ltd. (CN) | 2022-09-21 | — | — | EP | disclosed |
| CN-112851607-A | Amide derivative, preparation method and medical application thereof | 成都百裕制药股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| WO-2021093820-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2021093820-A1 | AMIDE DERIVATIVE AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2021-05-20 | — | — | WO | disclosed |
| WO-2015044073-A1 | PROCESS AND INTERMEDIATES FOR PREPARING INDANYLOXYDIHYDROBENZOFURANYL ACETIC ACID DERIVATIVES AS GPR40 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-02 | — | — | WO | disclosed |
| US-20150087829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING GPR40 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING GPR40 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING GPR40 AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| EP-2831053-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | Boehringer Ingelheim International GmbH (DE) | 2015-02-04 | — | — | EP | disclosed |
| US-8859584-B2 | TRPV1 antagonists | ABBVIE, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013144098-A1 | NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACID DERIVATIVES AND THEIR USE AS GPR40 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-03 | — | — | WO | disclosed |
| WO-2013096223-A1 | TRPV1 ANTAGONISTS | ABBVIE INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158067-A1 | TRPV1 Antagonists | ABBVIE INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11976054-B2 | Amide derivative and preparation method therefore and use thereof in medicine | NLRP3, NLRP1, PYCARD | EPAS1 2041/4885IL1RN 38/4885ERAP2 1787/4885 |
| US-20220411392-A1 | Amide Derivative And Preparation Method Therefore And Use Thereof In Medicine | NLRP3, NLRP1, PYCARD | EPAS1 2041/4885IL1RN 38/4885ERAP2 1787/4885 |
| US-20130158067-A1 | TRPV1 Antagonists | TRPV1, NPY1R, MRGPRX1 | EPAS1 1366/4885IL1RN 791/4885ERAP2 2293/4885 |
| US-20150087829-A1 | PROCESS AND INTERMEDIATES FOR PREPARING GPR40 AGONISTS | GPR4, GPR3, GPR55 | EPAS1 1052/4885IL1RN 1171/4885ERAP2 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.